0947 ET - While D. Boral Capital says Invivyd's guidance didn't include the potential expansion of its Pemgarda drug use, analyst Jason Kolbert says it shows the challenges in securing approvals for COVID-19 therapeutics and reinforces the importance of pipeline diversification to sustain long-term growth. Pemgarda is a monoclonal antibody medication authorized for the pre-exposure prophylaxis of COVID‑19. Kolbert says Invivyd remains engaged with the FDA in pursuit of a regulatory pathway for its medication while preparing to provide additional data and regulatory correspondence to underscore its position. Invivyd tumbles 27% to $1.30. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 09:48 ET (14:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。